- Home
- PEPG vs ME Comparison
PEPG vs ME Comparison
Compare PEPG & ME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEPG
- ME
- Stock Information
- Founded
- PEPG 2018
- ME 2006
- Country
- PEPG United States
- ME United States
- Employees
- PEPG N/A
- ME N/A
- Industry
- PEPG Biotechnology: Pharmaceutical Preparations
- ME Precision Instruments
- Sector
- PEPG Health Care
- ME Health Care
- Exchange
- PEPG Nasdaq
- ME Nasdaq
- Market Cap
- PEPG 118.3M
- ME 98.7M
- IPO Year
- PEPG 2022
- ME N/A
- Fundamental
- Price
- PEPG $2.08
- ME $3.58
- Analyst Decision
- PEPG Buy
- ME Hold
- Analyst Count
- PEPG 3
- ME 1
- Target Price
- PEPG $14.67
- ME $9.40
- AVG Volume (30 Days)
- PEPG 158.0K
- ME 226.1K
- Earning Date
- PEPG 03-05-2025
- ME 02-05-2025
- Dividend Yield
- PEPG N/A
- ME N/A
- EPS Growth
- PEPG N/A
- ME N/A
- EPS
- PEPG N/A
- ME N/A
- Revenue
- PEPG N/A
- ME $193,260,000.00
- Revenue This Year
- PEPG N/A
- ME $21.93
- Revenue Next Year
- PEPG N/A
- ME $17.31
- P/E Ratio
- PEPG N/A
- ME N/A
- Revenue Growth
- PEPG N/A
- ME N/A
- 52 Week Low
- PEPG $2.09
- ME $2.66
- 52 Week High
- PEPG $19.30
- ME $16.52
- Technical
- Relative Strength Index (RSI)
- PEPG 18.60
- ME 49.65
- Support Level
- PEPG $3.69
- ME $3.34
- Resistance Level
- PEPG $4.48
- ME $3.95
- Average True Range (ATR)
- PEPG 0.27
- ME 0.29
- MACD
- PEPG -0.09
- ME 0.02
- Stochastic Oscillator
- PEPG 0.25
- ME 41.75
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
About ME 23andMe Holding Co.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.